It was shown that small subpopulations of AXL-positive cells are present in untreated melanoma samples, as well as patient-derived xenografts (PDXs), implying that they can be positively selected in the presence of BRAF/MEK inhibitors. The gene discussed is MAP2K7; the disease is melanoma.